Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Treasury Shares (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Treasury Shares for 12 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares fell 19.04% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, down 19.04% year-over-year, with the annual reading at $3.2 million for FY2025, 19.04% down from the prior year.
  • Treasury Shares for Q4 2025 was $3.2 million at Theravance Biopharma, down from $3.7 million in the prior quarter.
  • The five-year high for Treasury Shares was $15.6 million in Q3 2023, with the low at $3.1 million in Q1 2024.
  • Average Treasury Shares over 5 years is $6.6 million, with a median of $4.5 million recorded in 2025.
  • The sharpest move saw Treasury Shares skyrocketed 1917.84% in 2021, then crashed 72.59% in 2024.
  • Over 5 years, Treasury Shares stood at $8.4 million in 2021, then skyrocketed by 52.49% to $12.7 million in 2022, then crashed by 68.63% to $4.0 million in 2023, then dropped by 1.01% to $4.0 million in 2024, then fell by 19.04% to $3.2 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $3.2 million, $3.7 million, and $4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.